Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study.

abstract：:Chronic obstructive pulmonary disease (COPD) is influenced by genetic and environmental factors. A large number of candidate gene-association studies and genome-wide linkage scans have been conducted to elucidate the genetic architecture underlying this disease. The compilation of these studies clearly revealed the co...

journal_title：Pharmacogenomics

authors： Bossé Y

更新日期：2009-04-01 00:00:00

abstract：:Evaluating the prospects for 'personalized healthcare' has become topical at the 10-year anniversary of the first results from the Human Genome Project. The coincidence of this milestone with a period of global financial difficulty is unfortunate, but industry has signaled its willingness to invest in this new medical...

journal_title：Pharmacogenomics

authors： Creeden J

更新日期：2012-11-01 00:00:00

abstract：:Evaluation of: Woynarowski JM, Krugliak M, Ginsburg H: Pharmacogenomic analyses of targeting the AT-rich malaria parasite genome with AT-specific alkylating drugs. Mol. Biochem. Parasitol. 154(1), 70-81 (2007) [1] . The sequencing of the malaria genome sought to expose the parasite's ability to cause disease and ident...

journal_title：Pharmacogenomics

authors： Yanow SK,Purcell LA,Lee M,Spithill TW

更新日期：2007-09-01 00:00:00

abstract：:Migraine is a paroxysmal neurological disorder affecting up to 6% of males and 18% of females in the general population, and has been demonstrated to have a strong, but complex, genetic component. Genetic investigation of migraine provides hope that new targets for medications and individual specific therapy will be d...

journal_title：Pharmacogenomics

authors： Fernandez F,Colson NJ,Griffiths LR

更新日期：2007-06-01 00:00:00

abstract：:Discovery Partners International (Nasdaq: DPII) is a leader in collaborative drug discovery. DPI's integrated discovery framework encompasses a broad spectrum of capabilities in chemistry, biology, informatics, computational modeling and synthesis automation. DPI's approach to drug discovery places a heavy emphasis on...

journal_title：Pharmacogenomics

authors： Herd C

更新日期：2002-01-01 00:00:00

abstract：:Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumar...

journal_title：Pharmacogenomics

authors： Voora D,McLeod HL,Eby C,Gage BF

更新日期：2005-07-01 00:00:00

abstract：AIMS:Carvedilol is an effective treatment in hypertension and chronic heart failure. The medical impact of polymorphisms in CYP2D6 and in the β-adrenergic receptors ADRB1 and ADRB2 on the pharmacokinetics and pharmacodynamics of carvedilol is controversial. METHODS:After carvedilol 25 mg was administered to 110 volunt...

journal_title：Pharmacogenomics

authors： Sehrt D,Meineke I,Tzvetkov M,Gültepe S,Brockmöller J

更新日期：2011-06-01 00:00:00

abstract：:This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute (INCA), targeting the cancer chemotherapeutic drugs - fluoropyrimidines, irinotecan and thiopurines. This initiative, designed as a research project, was support...

journal_title：Pharmacogenomics

authors： Suarez-Kurtz G,Kovaleski G,Elias AB,Motta V,Wolch K,Emerenciano M,Mansur MB,Palladino AM,Accioly MT,Ferreira M,Gonçalves AA,de Melo AC

更新日期：2020-06-01 00:00:00

abstract：:ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors. Recently, a shortly accumulated biomedical research clarified the numerous biological processes underlying its ability to support cancer development, growth and pro...

journal_title：Pharmacogenomics

authors： Palmirotta R,Quaresmini D,Lovero D,Silvestris F

更新日期：2017-02-01 00:00:00

abstract：:Glinides, including repaglinide, nateglinide and mitiglinide, are a type of fasting insulin secretagogue that could help to mimic early-phase insulin release, thus providing improved control of the postprandial glucose levels. Glinides stimulate insulin secretion by inhibiting ATP-sensitive potassium channels in the p...

journal_title：Pharmacogenomics

authors： Chen M,Hu C,Jia W

更新日期：2015-01-01 00:00:00

abstract：:Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

journal_title：Pharmacogenomics

authors： Zuiverloon TC,Theodorescu D

更新日期：2017-08-01 00:00:00

abstract：:Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regar...

journal_title：Pharmacogenomics

authors： Nickola TJ,Green JS,Harralson AF,O'Brien TJ

更新日期：2012-09-01 00:00:00

abstract：OBJECTIVE:We designed this trial to investigate if modifications in levels of circulating vascular endothelial growth factor (VEGF) may be related to clinical response and outcome in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. METHODS:A total of 45 heavi...

journal_title：Pharmacogenomics

authors： Vincenzi B,Santini D,Russo A,Gavasci M,Battistoni F,Dicuonzo G,Rocci L,Rosaria VM,Gebbia N,Tonini G

更新日期：2007-04-01 00:00:00

abstract：AIMS:Survivin (SVV) mRNA expression levels in peripheral blood of patients with gastrointestinal malignancies change significantly during the course of treatment. We wanted to scrutinize these findings in patients with esophageal carcinoma and furthermore evaluate whether the detection of mRNA and the change in detecti...

journal_title：Pharmacogenomics

authors： Hoffmann AC,Vallböhmer D,Grimminger P,Metzger R,Prenzel KL,Hoelscher AH,Brabender J

更新日期：2010-03-01 00:00:00

abstract：:Fibromyalgia syndrome (FMS) is a common chronic widespread pain syndrome mainly affecting women. Although the etiology of FMS is not completely understood, varieties of neuroendocrine disturbances, as well as abnormalities of autonomic function, have been implicated in its pathogenesis. The exposure of a genetically p...

journal_title：Pharmacogenomics

authors： Buskila D,Sarzi-Puttini P,Ablin JN

更新日期：2007-01-01 00:00:00

abstract：:Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...

journal_title：Pharmacogenomics

authors： Taylor DR,Kennedy MA

更新日期：2002-03-01 00:00:00

abstract：:The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

journal_title：Pharmacogenomics

authors： Hawkins GA,Weiss ST,Bleecker ER

更新日期：2008-03-01 00:00:00

abstract：:Fibrates are a medication class prescribed for decades as 'broad-spectrum' lipid-modifying agents used to lower blood triglyceride levels and raise high-density lipoprotein cholesterol levels. Such lipid changes are associated with a decrease in cardiovascular disease, and fibrates are commonly used to reduce risk of ...

journal_title：Pharmacogenomics

authors： House JS,Motsinger-Reif AA

更新日期：2020-03-01 00:00:00

abstract：AIM:This study evaluated the impact of SULT4A1 gene variation on psychopathology and antipsychotic drug response in Caucasian subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study and a replication sample. PATIENTS & METHODS:SULT4A1 haplotypes were determined using SNP data. The r...

journal_title：Pharmacogenomics

authors： Ramsey TL,Meltzer HY,Brock GN,Mehrotra B,Jayathilake K,Bobo WV,Brennan MD

更新日期：2011-04-01 00:00:00

abstract：AIM:GLP-1 plays a key role in glucose metabolism and influences antipsychotic-induced weight gain (AIWG). Our study is the first to investigate the encoding gene, GCG, and the GLP-1 receptor gene, GLP1R, and association with AIWG. MATERIALS & METHODS:In 216 schizophrenic patients treated with antipsychotics for up to ...

journal_title：Pharmacogenomics

authors： Brandl EJ,Tiwari AK,Chowdhury NI,Zai CC,Lieberman JA,Meltzer HY,Kennedy JL,Müller DJ

更新日期：2014-03-01 00:00:00

abstract：:Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarray technology covered the latest advances in this technology and applications in life sciences. Highlights of the meetings are reported briefly with emphasis on applications in genomics, drug discovery and molecular diagnostics. Ther...

journal_title：Pharmacogenomics

authors： Jain KK

更新日期：2001-02-01 00:00:00

abstract：:Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...

journal_title：Pharmacogenomics

authors： Abdolmaleky HM,Zhou JR,Thiagalingam S,Smith CL

更新日期：2008-12-01 00:00:00

abstract：:Recent research highlighted the large extent of rare variants in pharmacogenes and, on this basis, it was estimated that rare variants account for 30-40% of the functional variability in pharmacogenes. It has been proposed that comprehensive next-generation sequencing (NGS)-based sequencing of pharmacogenes could soon...

journal_title：Pharmacogenomics

authors： Lauschke VM,Ingelman-Sundberg M

更新日期：2016-06-01 00:00:00

abstract：:Damage to the heart can result from both traditional chemotherapeutic agents, such as doxorubicin, and newer 'targeted' therapies, such as trastuzumab. This chemotherapeutic cardiotoxicity is potentially life-threatening and necessitates limiting or discontinuing an otherwise-effective cancer treatment. Clinical strat...

journal_title：Pharmacogenomics

authors： Jensen BC,McLeod HL

更新日期：2013-01-01 00:00:00

abstract：:We report the case of a patient bearing a T315I-mutant chronic myeloid leukemia resistant to nilotinib, successfully treated with omacetaxine and then with dasatinib. After 9 months of nilotinib, the patient achieved a major molecular response but relapsed 3 months later due to the T315I mutation. Because third-genera...

journal_title：Pharmacogenomics

authors： Venton G,Colle J,Mercier C,Fanciullino R,Ciccolini J,Ivanov V,Suchon P,Sebahoun G,Beaufils N,Gabert J,Hadjaj D,Costello R

更新日期：2015-01-01 00:00:00

abstract：:The heterogeneous Brazilian population, with European, African and Amerindian ancestral roots is a model case for exploring the impact of population admixture on the frequency distribution of polymorphisms in pharmacogenes, and the design and interpretation of pharmacogenomics trials. Examples drawn from studies carri...

journal_title：Pharmacogenomics

authors： Suarez-Kurtz G,Paula DP,Struchiner CJ

更新日期：2014-02-01 00:00:00

abstract：:Aim: Major drawbacks of percutaneous coronary intervention are the high occurrence of repeat revascularization due to restenosis and disease progression. The aim of this study was to find genetic indicators to predict the risk of repeat revascularization. Materials & methods: From April 2015 to June 2016, 143 patients...

journal_title：Pharmacogenomics

authors： Xiang Q,Liu Z,Lu Y,Mao J,Chen S,Zhao X,Zhou S,Xie Q,Wang Z,Mu G,Jiang J,Gong Y,Cui Y

更新日期：2020-01-01 00:00:00

abstract：:Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...

journal_title：Pharmacogenomics

authors： Schumacher-Schuh AF,Rieder CR,Hutz MH

更新日期：2014-06-01 00:00:00

abstract：:The investigational drug dichloroacetate (DCA) is a metabolic regulator that has been successfully used to treat acquired and congenital metabolic diseases and, recently, solid tumors. Its clinical use has revealed challenges in selecting appropriate doses. Chronic administration of DCA leads to inhibition of DCA meta...

journal_title：Pharmacogenomics

authors： James MO,Stacpoole PW

更新日期：2016-05-01 00:00:00

abstract：:For the last 40 years, 5-fluorouracil (5-FU) has remained the treatment of choice in both the adjuvant and advanced treatment of colorectal cancer (CRC). However, 5-FU monotherapy produces response rates of only 10-20% in the advanced setting. 5-FU has been combined with newer agents, such as oxaliplatin and irinoteca...

journal_title：Pharmacogenomics

authors： Allen WL,Johnston PG

更新日期：2005-09-01 00:00:00